Jurado-Martin I, Ma C, Rezk N, Sainz-Mejias M, Hou Y, Baugh J
Access Microbiol. 2024; 6(11).
PMID: 39575441
PMC: 11580749.
DOI: 10.1099/acmi.0.000860.v3.
Esposito A, Rossi A, Stabile M, Pinto G, De Fino I, Melessike M
ACS Pharmacol Transl Sci. 2024; 7(6):1807-1822.
PMID: 38898954
PMC: 11184606.
DOI: 10.1021/acsptsci.4c00044.
Dartois V, Bonfield T, Boyce J, Daley C, Dick T, Gonzalez-Juarrero M
Tuberculosis (Edinb). 2024; 147:102503.
PMID: 38729070
PMC: 11168888.
DOI: 10.1016/j.tube.2024.102503.
Cigana C, Rossi A, Alcala-Franco B, Bragonzi A
Methods Mol Biol. 2023; 2721:215-231.
PMID: 37819525
DOI: 10.1007/978-1-0716-3473-8_15.
Wills B, Garai P, Riegert M, Sanchez F, Pickrum A, Frank D
Infect Immun. 2023; 91(7):e0003723.
PMID: 37255468
PMC: 10353400.
DOI: 10.1128/iai.00037-23.
Lung infection by Pseudomonas aeruginosa induces neuroinflammation and blood-brain barrier dysfunction in mice.
Villalba N, Ma Y, Gahan S, Joly-Amado A, Spence S, Yang X
J Neuroinflammation. 2023; 20(1):127.
PMID: 37245027
PMC: 10223932.
DOI: 10.1186/s12974-023-02817-7.
Butyrate regulates neutrophil homeostasis and impairs early antimicrobial activity in the lung.
Dang A, Begka C, Pattaroni C, Caley L, Floto R, Peckham D
Mucosal Immunol. 2023; 16(4):476-485.
PMID: 37178819
PMC: 10412508.
DOI: 10.1016/j.mucimm.2023.05.005.
Persistence Level Reflects Antibiotic Survival of Natural Pseudomonas aeruginosa Isolates in a Murine Lung Infection Model.
Verstraete L, Aizawa J, Govaerts M, De Vooght L, Lavigne R, Michiels J
Microbiol Spectr. 2023; 11(3):e0497022.
PMID: 37140371
PMC: 10269860.
DOI: 10.1128/spectrum.04970-22.
Lung infection by P. aeruginosa induces neuroinflammation and blood-brain barrier dysfunction in mice.
Villalba N, Ma Y, Gahan S, Joly-Amado A, Spence S, Yang X
Res Sq. 2023; .
PMID: 36778380
PMC: 9915779.
DOI: 10.21203/rs.3.rs-2511441/v1.
Selected strategies to fight pathogenic bacteria.
Plotniece A, Sobolev A, Supuran C, Carta F, Bjorkling F, Franzyk H
J Enzyme Inhib Med Chem. 2023; 38(1):2155816.
PMID: 36629427
PMC: 9848314.
DOI: 10.1080/14756366.2022.2155816.
Towards Translation of PqsR Inverse Agonists: From In Vitro Efficacy Optimization to In Vivo Proof-of-Principle.
Hamed M, Abdelsamie A, Rox K, Schutz C, Kany A, Rohrig T
Adv Sci (Weinh). 2023; 10(5):e2204443.
PMID: 36596691
PMC: 9929129.
DOI: 10.1002/advs.202204443.
New TMA (4,6,4'-Trimethyl angelicin) Analogues as Anti-Inflammatory Agents in the Treatment of Cystic Fibrosis Lung Disease.
Tupini C, Chilin A, Rossi A, De Fino I, Bragonzi A, DAversa E
Int J Mol Sci. 2022; 23(22).
PMID: 36430961
PMC: 9699093.
DOI: 10.3390/ijms232214483.
Pamoic acid is an inhibitor of HMGB1·CXCL12 elicited chemotaxis and reduces inflammation in murine models of Pseudomonas aeruginosa pneumonia.
De Leo F, Rossi A, De Marchis F, Cigana C, Melessike M, Quilici G
Mol Med. 2022; 28(1):108.
PMID: 36071400
PMC: 9449960.
DOI: 10.1186/s10020-022-00535-z.
Probability of Target Attainment of Tobramycin Treatment in Acute and Chronic Lung Infection Based on Preclinical Population Pharmacokinetic Modeling.
Dias B, Carreno F, Helfer V, Garzella P, Lima D, Barreto F
Pharmaceutics. 2022; 14(6).
PMID: 35745809
PMC: 9228144.
DOI: 10.3390/pharmaceutics14061237.
Lung and Gut Microbiota Changes Associated with Infection in Mouse Models of Cystic Fibrosis.
Bacci G, Rossi A, Armanini F, Cangioli L, De Fino I, Segata N
Int J Mol Sci. 2021; 22(22).
PMID: 34830048
PMC: 8625166.
DOI: 10.3390/ijms222212169.
Type-4 Phosphodiesterase (PDE4) Blockade Reduces NETosis in Cystic Fibrosis.
Totani L, Amore C, Piccoli A, DellElba G, Di Santo A, Plebani R
Front Pharmacol. 2021; 12:702677.
PMID: 34566635
PMC: 8456009.
DOI: 10.3389/fphar.2021.702677.
Absence of pro-survival A1 has no impact on inflammatory cell survival in vivo during acute lung inflammation and peritonitis.
Gangoda L, Schenk R, Best S, Nedeva C, Louis C, DSilva D
Cell Death Differ. 2021; 29(1):96-104.
PMID: 34304242
PMC: 8738744.
DOI: 10.1038/s41418-021-00839-3.
A New PqsR Inverse Agonist Potentiates Tobramycin Efficacy to Eradicate Pseudomonas aeruginosa Biofilms.
Schutz C, Ho D, Hamed M, Abdelsamie A, Rohrig T, Herr C
Adv Sci (Weinh). 2021; 8(12):e2004369.
PMID: 34165899
PMC: 8224453.
DOI: 10.1002/advs.202004369.
Enhancing Cystic Fibrosis Immune Regulation.
van Heeckeren A, Sutton M, Fletcher D, Hodges C, Caplan A, Bonfield T
Front Pharmacol. 2021; 12:573065.
PMID: 34054509
PMC: 8155373.
DOI: 10.3389/fphar.2021.573065.
Donor-defined mesenchymal stem cell antimicrobial potency against nontuberculous mycobacterium.
Bonfield T, Sutton M, Fletcher D, Folz M, Ragavapuram V, Somoza R
Stem Cells Transl Med. 2021; 10(8):1202-1216.
PMID: 33943038
PMC: 8284776.
DOI: 10.1002/sctm.20-0521.